National Cancer Institute (NCI)


FLC Region

Security Lab



9609 Medical Center Drive
Bethesda, MD 20892
United States

Laboratory Representative


The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS) in the Department of Health and Human Services (DHHS). The NCI, established under the National Cancer Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice.

The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Accomplishments in Technology Transfer:

AIDS test kits, Fludara®, Gardasil®, HIVID®, Kepivance®, Multi-replica blotting kit for proteins, NeuTrexin®, PathVysion® HER-2 DNA probe kit, PhenoSenseTM HIV phenotype tests, PixCell® Laser Capture Microdissection system (LCM), Prezista®, soluble IL-2 receptor assays, Squirrel-Free capsaicin-treated birdseed, Taxol®, Velcade®, Videx®, Vitravene® and Zevalin®. More information on NCI success stories can be found at


The National Cancer Institute supports and coordinate research projects conducted by universities, hospitals, research foundations, and businesses throughout this country and abroad through research grants and cooperative agreements; conducts research in its own laboratories and clinics; supports education and training in fundamental sciences and clinical disciplines for participation in basic and clinical research programs and treatment programs relating to cancer through career awards, training grants, and fellowships; supports research projects in cancer control; supports a national network of cancer centers; collaborates with voluntary organizations and other national and foreign institutions engaged in cancer research and training activities; encourages and coordinates cancer research by industrial concerns where such concerns evidence a particular capability for programmatic research; collects and disseminates information on cancer; supports construction of laboratories, clinics, and related facilities necessary for cancer research through the award of construction grants.

Tech Areas

Available Technologies
Displaying 1 - 10 of 944
1,2-Dihydroellipticines with Activity Against CNS-Specific Cancer Cell Lines
15kD Granulysin for Monocyte Differentiation: A New Immunotherapeutic for Both in vivo and ex vivo Applications
15kD Granulysin for Monocyte Differentiation: A New Immunotherapeutic for Both in vivo and ex vivo Applications
17-AAG Treatment of Diseases Sensitive to c-KIT Down Regulation
2-Amino-O4-Substituted Pteridines: Improved Chemotherapy Adjuvants
3-Deazaneplanocin, Intermediates for It, and Antiviral Composition and Method of Treatment Using It
3D Image Rendering Softwarefor Biological Tissues
5-Substituted Derivatives of Conformationally Locked Nucleoside Analogues
888-mel: A Target for Anti-Tumor Immune Responses
89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods


No Funding for this lab
No Programs for this lab
Displaying 1 - 6 of 6
Advanced Technology Research Facility (ATRF)
Division of Cancer Treatment and Diagnosis
Frederick National Laboratory for Cancer Research
Laboratory of Molecular Technology
Nanotechnology Characterization Lab
The NCI Experimental Program NeXT
No Equipment for this lab
No publications for this lab
No news for this lab
Submit an Article
Success Stories
Submit an Success Story

The National Cancer Institute Formulary

The National Cancer Institute (NCI) agent formulary (NCI Formulary) was launched on January 11, 2017 as one of the first efforts of the Cancer Moonshot initiative. To develop the NCI Formulary, the Cancer Therapy Evaluation Program (CTEP), DCTD, NCI negotiated specific NCI Formulary Clinical cooperative research and development agreements (CRADAs) with pharmaceutical company collaborators that agreed to expand the use of their proprietary agents for studies supported by the NCI Formulary. The NCI Formulary CRADAs provide NCI-audited academic institutions access to these proprietary agents, thus eliminating the often-lengthy agent access process that occurs between such institutions and pharmaceutical companies.

Agents within the NCI Formulary are available to investigators at NCI-audited clinical sites for the conduct of clinical trials under investigator-held investigational new drug applications (INDs), as well as for pre-clinical research. CTEP’s clinical trial infrastructure will facilitate the conduct of the trials, from proposal submission and timely review by the collaborating pharmaceutical companies to agent distribution, serious adverse event submission, and clinical data reporting, while providing a coordination mechanism between the clinical investigators and the pharmaceutical company collaborators. A clinical Material Transfer Agreement between NCI and the clinical sites will formalize the expectations of each party.

CRADA Outcome

To date, CTEP has successfully negotiated CRADAs with 9 different pharmaceutical companies to bring 27 different agents into the NCI Formulary. All of these potential cancer treatments are now available to over 300 different cancer centers and clinical trial sites that have been audited by NCI. One of the big advantages of the program is the ease with which combination trials can be set up using the Formulary. In addition, applications can be made by academic investigators to use the agents in non-clinical research.

The NCI Formulary allows for:

  • Negotiation-free access to investigators through the NCI template agreement with the participating companies
  • Less time to acquire the agents
  • Unique opportunities to obtain agent from multiple companies to combine in one study
  • The distribution of agents to occur at no cost to the investigator
  • Enhances the clinical trial implementation process
  • The Investigator to have control over the initial publication and presentation of the results
  • An evolving list of agents from collaborating companies (see